AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) These designations represent the...
Covered in this story
What has happened since
- California Resources Corp is up 1.7% since this was published, 15 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on California Resources Corp
- UBS: $53.7 → $68 by Oct 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $CRC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on California Resources Corp →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.